Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that positive preclinical data from its next generationComPACT platform technology, which combines a T cell priming vaccine and T cell co-stimulator in a single product, were presented as both an oral presentation and poster at the Keystone Symposia on Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, held in Whistler, British Columbia, Canada on March 6-10, 2016. Data presented showed that ComPACT secreting OX40L generated the most potent immune response among other ComPACT co-stimulator variations including TL1A, 4-1BBL and ICOSL, as well as compared to systemic delivery of OX40 agonist antibody and vaccine alone.
A copy of the poster entitled “Combination Immunotherapy: T cell costimulation (OX40L, TL1A, 4-1BBL and ICOSL) secreted locally by Gp96-Ig vaccines elicits robust antigen-specific memory T cell responses and tumor elimination” will be made available in the Publications section of Heat’s corporate website.
About ComPACT
Currently in preclinical development, ComPACT represents a potential dual-acting immunotherapy, combining a pan-antigen T cell priming vaccine and a T cell co-stimulator in a single product. Heat has developed its first ComPACT product candidate, HS-120, as a potential treatment for non-small cell lung cancer (NSCLC) and anticipates filing an Investigational New Drug (IND) application by the end of 2016.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential of ComPACT as a dual-acting immunotherapy and treatment for NSCLC, the anticipated filing of an IND application by the end of 2016. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat’s ImPACT andComPACT therapies to perform as designed, the ability to enroll patients and complete the clinical trials on time, the other factors described in our annual report on Form 10-K for the year ended December 31, 2015 and our other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.